Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Okajima

P3.01-90 a Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev

Journal of Thoracic Oncology

English

Elimination of Teicoplanin by Adsorption to the Filter Membrane During Haemodiafiltration: Screening Experiments for Linezolid, Teicoplanin and Vancomycin Followed by in Vitro Haemodiafiltration Models for Teicoplanin

Anaesthesia and Intensive Care

Critical Care

Anesthesiology

Pain Medicine

Intensive Care Medicine

2012

English

Related publications

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)

Journal of Thoracic Oncology

English

MA 17.06 Safety Data From Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined With TRT for Locally Advanced Non-Squamous NSCLC

Journal of Thoracic Oncology

English

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

English

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Journal of Thoracic Oncology

English

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

Biologics: Targets and Therapy

English

P089 an EGFR KDD Data in the Chinese NSCLC Population and the Response to EGFR-TKIs: A Multicenter Study

Journal of Thoracic Oncology

English

P3.01-92 Blood Test Parameters as Prognostic Factors in EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs

Journal of Thoracic Oncology

English

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

Journal of Thoracic Oncology

English

P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by M. Okajima

P3.01-90 a Phase II Study Evaluating Continuation of EGFR-TKIs Beyond Progressive Disease Followed by the Addition of CDDP+PEM+Bev

Elimination of Teicoplanin by Adsorption to the Filter Membrane During Haemodiafiltration: Screening Experiments for Linezolid, Teicoplanin and Vancomycin Followed by in Vitro Haemodiafiltration Models for Teicoplanin

Related publications

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)

MA 17.06 Safety Data From Randomized Phase II Study of CDDP+S-1 vs CDDP+PEM Combined With TRT for Locally Advanced Non-Squamous NSCLC

Osimertinib With Ramucirumab in EGFR Mutated, T790m-Positive Patients Who Had Progressed EGFR-TKIs: Phase Ib Study

P3.01-16 Low Dose Apatinib Combined With EGFR-TKI in Treating Advanced NSCLC After First-Generation EGFR-TKIs Treatment Failure

Combination of EGFR-TKIs With Chemotherapy Versus Chemotherapy or EGFR-TKIs Alone in Advanced NSCLC Patients With EGFR Mutation

P089 an EGFR KDD Data in the Chinese NSCLC Population and the Response to EGFR-TKIs: A Multicenter Study

P3.01-92 Blood Test Parameters as Prognostic Factors in EGFR-Mutated Non-Small Cell Lung Cancer Treated With TKIs

P1.13-27 a Randomized Study of Concurrent vs Sequential Alternating EGFR-TKIs and Chemotherapy for Advanced NSCLC With EGFR Mutations

P3.01-37 Phase II Study of Amrubicin Plus Erlotinib in Previously Treated, Advanced Non-Small Cell Lung Cancer Patients With Wild-Type EGFR: TORG 1320